26 results
8-K
EX-99.1
IOBT
IO Biotech Inc
14 May 24
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
8:30am
to combination treatment post-surgery. The primary endpoint is major pathological response at surgery (≤10% residual viable tumor; central assessment). IO
8-K
EX-99.2
7etl1qjp05slb qm2
7 Aug 23
IO Biotech, Inc. Announces $75 Million Private Placement Financing
8:31am
8-K
EX-10.2
424u9lb18wfpojonx19q
7 Aug 23
IO Biotech, Inc. Announces $75 Million Private Placement Financing
8:31am
8-K
EX-10.1
xwx2tkjpyia1uo7
7 Aug 23
IO Biotech, Inc. Announces $75 Million Private Placement Financing
8:31am
PRE 14A
oduiza3y0
14 Apr 23
Preliminary proxy
4:39pm
DEF 14A
bfl0oxg
14 Apr 22
Definitive proxy
4:02pm
10-K
ic1qe2iujkus y2
31 Mar 22
Annual report
5:07pm
10-Q
xwy9 b2tezrs
17 Dec 21
Quarterly report
4:55pm
8-K
EX-10.1
dzdpz w19
6 Dec 21
Entry into a Material Definitive Agreement
9:00am
424B4
slt57fnfhk1ctr
8 Nov 21
Prospectus supplement with pricing info
5:20pm